Form 26AS evidence requires successor-entity accounting verification after business transfer, while invoice-supported related-party advertising expend...
Money-laundering judgment timing requires awaiting the scheduled-offence decision despite continuation of the underlying trial where outcomes directly...
Accredited investor eligibility expands through securities-market exposure, while alternative investment fund disputes require prescribed resolution a...
Page of 4916
Press 'Enter' after typing page number.
41 to 60 of 98302 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
This notification amends the CGST Rate Schedule u/s 9(1) of the Central Goods and Services Tax Act, 2017. It inserts three new items (Trastuzumab Deruxtecan, Osimertinib, Durvalumab) under the 2.5% tax rate schedule. It adds extruded or expanded savoury/salted products under the 6% tax rate. It modifies the 9% rate schedule by substituting the entry for un-fried/un-cooked snack pellets and seats other than aircraft/motor vehicle seats. It inserts a new entry for seats of motor vehicles under the 14% tax rate. The notification comes into force on 10th October 2024.
This notification amends the CGST Rate Schedule u/s 9(1) of the Central Goods and Services Tax Act, 2017. It inserts three new items (Trastuzumab Deruxtecan, Osimertinib, Durvalumab) under the 2.5% tax rate schedule. It adds extruded or expanded savoury/salted products under the 6% tax rate. It modifies the 9% rate schedule by substituting the entry for un-fried/un-cooked snack pellets and seats other than aircraft/motor vehicle seats. It inserts a new entry for seats of motor vehicles under the 14% tax rate. The notification comes into force on 10th October 2024.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
TaxTMI 
of 4916 
